2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy
No abstract yet
We only have this paper's title and publication details.
Read it at the sourceDiscussion
No takes yet. Share an insight, caveat, or question.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Shared decision-making, a dialogue between patients and their care team that includes full disclosure of all testing and treatment options, discussion of the risks and benefits of those options and, importantly, engagement of the patient to express their own goals, is particularly relevant in the management of conditions such as hypertrophic cardiomyopathy. This updated guideline places emphasis on including the patient in the decision-making process rather than simply providing dogmatic lists of do's and don'ts.”
“The guideline puts the patient front and center in the shared decision-making process and emphasizes the importance of incorporating patient's lifestyle choices and preferences when making complex, life-altering decisions.”
“Sudden cardiac death risk stratification evolved and now the toolset, independently produced by the ACC and AHA, allows use of risk factor-based recommendations and 5-year risk prediction to help patients understand the magnitude of their risk as they contemplate whether to pursue [implantable cardioverter defibrillator] placement. However, sudden cardiac death risk assessment continues to evolve and the current prediction tool does not account for several of the newer risk markers.”
Cite This Study
Ommen et al. (2020) studied this question.